TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23079311

Group type: EXPERIMENTAL
Intervention: Acrysof Restor SN6AD3 apodized multifocal IOL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AT LISA 366D diffractive multifocal IOL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tecnis ZMA00 diffractive multifocal IOL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rezoom refractive multifocal IOL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acri.Smart 48S monofocal IOL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (monofocal and refractive multifocal IOLs)
Number of subjects: 0
Study: 19578230

Group type: EXPERIMENTAL
Intervention: Intravenous human albumin 20% (1 g/kg) one hour before exchange
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group underwent a blood exchange
Number of subjects: 50
Study: 18725147

Group type: EXPERIMENTAL
Intervention: TTM-based, stage-tailored Internet program, F&V Express Bites
Number of subjects: 160

Group type: COMPARATOR
Intervention: Nontailored messages
Number of subjects: 160
Study: 16078036

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori (HP) eradication therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) monotherapy
Number of subjects: 17
Study: 12494080

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0
Study: 10367046

Group type: EXPERIMENTAL
Intervention: Low-dose intermittent MFP (3 months on, 1 month off) with 1000 mg calcium/day (average daily fluoride ion dose of 11.2 mg)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Continuous MFP with 1000 mg calcium/day (20 mg fluoride ions per day)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Calcium alone (1000 mg/day)
Number of subjects: 134
Study: 7499031

Group type: EXPERIMENTAL
Intervention: 1.5-MAC sevoflurane, isoflurane, or enflurane
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 2.5-MAC sevoflurane, isoflurane, or enflurane
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (medium alone)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nonanesthetic (air exposure)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All anesthetics (1.5-MAC and 2.5-MAC)
Number of subjects: 31
Study: 2019084

Group type: EXPERIMENTAL
Intervention: Selection of subjects with DMFT greater than 4 and at least three permanent second molars erupted
Number of subjects: 3005
Study: 6780232

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (continuous infusion over 48 hours initiated within 8 hours after onset of symptoms)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (late intervention, therapy begun more than 8 hours after onset of symptoms)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no nitroglycerin treatment)
Number of subjects: 31
Study: 31619359

Group type: EXPERIMENTAL
Intervention: Topical natamycin 5% alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical natamycin 5% plus CXL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical amphotericin B 0.15% alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical amphotericin 0.15% plus CXL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CXL regardless of medication
Number of subjects: 0
Study: 31248663

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28295141

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 196

Group type: COMPARATOR
Intervention: All AChEIs
Number of subjects: 196
Study: 26920594

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Fully adherent patients
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Partially adherent patients
Number of subjects: 388

Group type: COMPARATOR
Intervention: Nonadherent patients
Number of subjects: 388
Study: 25503627

Group type: EXPERIMENTAL
Intervention: Workplace social capital intervention (team building courses, public services, psychological consultation, outdoor training)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 447
Study: 23111090

Group type: EXPERIMENTAL
Intervention: Single port/incision laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard three-port laparoscopic surgery
Number of subjects: 0
Study: 20708576

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxcarbazepine
Number of subjects: 0
Study: 17068160

Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance training (RMT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham training (CON)
Number of subjects: 21
Study: 16280443

Group type: EXPERIMENTAL
Intervention: Vitamin A (50,000 IU for ages 2‐12 months; 100,000 IU for ages >12‐59 months)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 12198018

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (714 mg/d for 12 months)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 10200128

Group type: EXPERIMENTAL
Intervention: Single 2 g/kg dose of IVGG
Number of subjects: 203

Group type: COMPARATOR
Intervention: Non-IVGG treatment
Number of subjects: 203

Group type: COMPARATOR
Intervention: 400 mg/kg per day for 5 consecutive days of IVGG
Number of subjects: 203
Study: 1456570

Group type: EXPERIMENTAL
Intervention: Prednisone 50 mg at 1500 h
Number of subjects: 7

Group type: COMPARATOR
Intervention: Prednisone 50 mg at 0800 h
Number of subjects: 7

Group type: COMPARATOR
Intervention: Prednisone 50 mg at 2000 h
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3969541

Group type: EXPERIMENTAL
Intervention: 10 mg metolazone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 160 mg furosemide
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 10 mg pindolol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 100 mg hydralazine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Diuretic monotherapy (metolazone or furosemide)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination of three different antihypertensive agents
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Stepped-care approach
Number of subjects: 35
Study: 31114137

Group type: EXPERIMENTAL
Intervention: Probiotics (Bacillus subtilis and Enterococcus faecium) with esomeprazole 20 mg b.i.d. for 8 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo with esomeprazole 20 mg b.i.d. for 8 weeks
Number of subjects: 134
Study: 30129913

Group type: EXPERIMENTAL
Intervention: Intuitive triage
Number of subjects: 0

Group type: COMPARATOR
Intervention: START triage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intuitive triage and START
Number of subjects: 0
Study: 26299677

Group type: EXPERIMENTAL
Intervention: Baseline heart rate in sinus rhythm
Number of subjects: 5164

Group type: EXPERIMENTAL
Intervention: Baseline heart rate >114 bpm in atrial fibrillation
Number of subjects: 5164

Group type: COMPARATOR
Intervention: Baseline heart rate 90-114 bpm in atrial fibrillation
Number of subjects: 5164
Study: 26206311

Group type: EXPERIMENTAL
Intervention: Telerehabilitation program combined with conventional cardiac rehabilitation (n=70)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation alone (n=70)
Number of subjects: 140
Study: 23812240

Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: ART initiation
Number of subjects: 440
Study: 21099198

Group type: EXPERIMENTAL
Intervention: Ethyl chloride (EC) spray
Number of subjects: 51

Group type: COMPARATOR
Intervention: Saline spray (placebo)
Number of subjects: 51
Study: 18199135

Group type: EXPERIMENTAL
Intervention: Group care (83 patients, 27 Type 1 and 56 Type 2)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control subjects (79 patients, 28 Type 1 and 51 Type 2)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Group care (Type 1 diabetes)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control subjects (Type 1 diabetes)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Group care (Type 2 diabetes)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control subjects (Type 2 diabetes)
Number of subjects: 162
Study: 17012873

Group type: EXPERIMENTAL
Intervention: ChimeriVax-DEN2 (high dose, 5 log PFU)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ChimeriVax-DEN2 (low dose, 3 log PFU)
Number of subjects: 56

Group type: COMPARATOR
Intervention: YF-VAX
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ChimeriVax-DEN2 (high dose) in YF immune subjects
Number of subjects: 56

Group type: COMPARATOR
Intervention: ChimeriVax-DEN2 and YF-VAX
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ChimeriVax-DEN2 in YF immune subjects
Number of subjects: 56
Study: 14617474

Group type: EXPERIMENTAL
Intervention: GnRHa (buserelin acetate, 900 microg/day for 10-12 weeks followed by 4 weeks postoperative treatment)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 15
Study: 11063436

Group type: EXPERIMENTAL
Intervention: 1 L/d of paper-filtered coffee brewed with 70 g regular ground beans
Number of subjects: 26

Group type: COMPARATOR
Intervention: No coffee
Number of subjects: 26
Study: 9160935

Group type: EXPERIMENTAL
Intervention: Nailing with reaming
Number of subjects: 135

Group type: COMPARATOR
Intervention: Nailing without reaming
Number of subjects: 135
Study: 8428870

Group type: EXPERIMENTAL
Intervention: Methylphenidate alone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Methylphenidate in combination with behavioral parent training plus child self-control instruction
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 96
Study: 3619741

Group type: EXPERIMENTAL
Intervention: 20 mg of intravenous metoclopramide hydrochloride
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 100
Study: 30359821

Group type: EXPERIMENTAL
Intervention: Stereotype content assessment for Black and poor children
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Stereotype strength assessment for constructs related to race-abuse and social class-abuse
Number of subjects: 93
Study: 27219616

Group type: EXPERIMENTAL
Intervention: Beta-blockers (Metoprolol, 37±13.5 mg, n=48)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No beta-blockers (n=52)
Number of subjects: 100
Study: 24593273

Group type: EXPERIMENTAL
Intervention: Long-term administration of itraconazole (ITCZ) - 400 mg/day for 2 days followed by 200 mg/day until day +90 post transplantation.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Short-term administration of itraconazole (ITCZ) - 400 mg/day for 2 days followed by 200 mg/day until day +30 post transplantation.
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Long-term administration of itraconazole (ITCZ) from day +30 to day +90.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Short-term administration of itraconazole (ITCZ) from day +30 to day +90.
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Long-term administration of itraconazole (ITCZ) - drug-related adverse events.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Short-term administration of itraconazole (ITCZ) - drug-related adverse events.
Number of subjects: 128
Study: 22536073

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (2.4 g omega-3, 1800 mg eicosapentaenoic acid + 600 mg docosahexaenoic acid)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 20688775

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (30 mg/kg over 10 minutes in normal saline)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (5 ml over 10 minutes)
Number of subjects: 50
Study: 18454609

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion (CSCI) of opioid for 48 hours
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intermittent subcutaneous injections (ISCI) of opioid for 48 hours
Number of subjects: 11
Study: 15720906

Group type: EXPERIMENTAL
Intervention: Minimally invasive carpal tunnel decompression
Number of subjects: 194

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 194
Study: 12578516

Group type: EXPERIMENTAL
Intervention: Nurse Telemanagement (NTM)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Nurse Telemanagement (NTM) and Home Nurse Visit (HNV)
Number of subjects: 216
Study: 10563072

Group type: EXPERIMENTAL
Intervention: Perindopril 4-8 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Enalapril 10-20 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Perindopril and Enalapril
Number of subjects: 32
Study: 8690820

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus epoprostenol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 23
Study: 1737346

Group type: EXPERIMENTAL
Intervention: rIFN gamma and rIFN alpha
Number of subjects: 28
Study: 6503242

Group type: COMPARATOR
Intervention: Adult talk (5 min)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Mixed condition (alternating 30-s periods of silence and talk)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Modified talk (question or comment every 10 s)
Number of subjects: 3
Study: 30700482

Group type: EXPERIMENTAL
Intervention: Personalised telehealth intervention (one telephone call per fortnight and 2-8 tailored text messages for 3 months, followed by 4-12 tailored text messages for 3 months without telephone calls)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care followed by non-tailored education-only text messages for 3 months
Number of subjects: 80
Study: 30132926

Group type: EXPERIMENTAL
Intervention: Uninterrupted NOAC therapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Interrupted NOAC therapy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study: 26770041

Group type: EXPERIMENTAL
Intervention: Avaxim™
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epaxal®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Havrix®
Number of subjects: 0
Study: 25142484

Group type: EXPERIMENTAL
Intervention: Ground-based walking training (supervised, 2-3 times a week for 8-10 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 130
Study: 22357633

Group type: EXPERIMENTAL
Intervention: Functional Task Practice (FTP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dynamic Resistance Training (POWER)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Treatment order B (POWER followed by FTP)
Number of subjects: 14
Study: 19071128

Group type: EXPERIMENTAL
Intervention: Metyrapone (1500 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17237450

Group type: EXPERIMENTAL
Intervention: Participants informed of morbidity costs
Number of subjects: 181

Group type: COMPARATOR
Intervention: Participants uninformed of morbidity costs
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Illness severity levels
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Interaction between illness severity and prior knowledge
Number of subjects: 181
Study: 16190818

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy in patients with rapid noncomplicated healing of leg fractures
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy in patients with protracted healing and undergoing surgical reconstructions
Number of subjects: 2
Study: 12493085

Group type: EXPERIMENTAL
Intervention: High-fat breakfast with predominantly saturated fatty acids (SFA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-fat breakfast with n-6 polyunsaturated fatty acids (PUFA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-fat breakfast with long-chain n-3 PUFA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-fat breakfast with monounsaturated fatty acids (MUFA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate lunch (5.7 g fat)
Number of subjects: 10
Study: 9609272

Group type: EXPERIMENTAL
Intervention: Two-stage postpartum perineal repair leaving the skin unsutured
Number of subjects: 1780

Group type: COMPARATOR
Intervention: Three-stage repair including skin closure with interrupted or subcuticular sutures
Number of subjects: 1780
Study: 7639167

Group type: EXPERIMENTAL
Intervention: Participation in the TIMI 5 trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex trials designed to improve reperfusion therapy
Number of subjects: 0
Study: 2093803

Group type: EXPERIMENTAL
Intervention: Breath‐Taker peak flow meter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: mini‐Wright peak flow meter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Wright peak flow meter
Number of subjects: 30

Group type: COMPARATOR
Intervention: pneumotachograph system
Number of subjects: 30
Study: 934747

Group type: EXPERIMENTAL
Intervention: Primary pediatric care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Episodic care (Control)
Number of subjects: 0
Study: 29373698

Group type: EXPERIMENTAL
Intervention: Snus alone
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Snus plus information
Number of subjects: 649

Group type: COMPARATOR
Intervention: Nicotine lozenge
Number of subjects: 649
Study: 28368672

Group type: EXPERIMENTAL
Intervention: Intensive arm (idarubicin 9 mg/m2 daily for 3 days)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Standard arm (idarubicin 9 mg/m2 daily for 2 days)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Intensive arm
Number of subjects: 293

Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 293
Study: 25381472

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection (40 mg/1 ml methylprednisolone acetate)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Blinded corticosteroid injection (40 mg/1 ml methylprednisolone acetate)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups (USG and BIG)
Number of subjects: 74
Study: 23991656

Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration followed by PCI
Number of subjects: 7244

Group type: COMPARATOR
Intervention: PCI only
Number of subjects: 7244
Study: 22080022

Group type: EXPERIMENTAL
Intervention: Ad libitum feeding regimen
Number of subjects: 6

Group type: COMPARATOR
Intervention: Restrict feeding regimen
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Different turkey genotypes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Different feeding regimens
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PCA methodology
Number of subjects: 6
Study: 18815153

Group type: EXPERIMENTAL
Intervention: Modular behavioural education programme
Number of subjects: 218

Group type: COMPARATOR
Intervention: Standard information-focused education programme
Number of subjects: 218
Study: 17062303

Group type: EXPERIMENTAL
Intervention: IV pantoprazole 160 mg/d for 3 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Omeprazole 160 mg/d for 3 days
Number of subjects: 40
Study: 14597860

Group type: EXPERIMENTAL
Intervention: Orlistat 360 mg/day plus hypocaloric diet
Number of subjects: 204

Group type: COMPARATOR
Intervention: Calorie‐restricted diet alone
Number of subjects: 204
Study: 10954007

Group type: EXPERIMENTAL
Intervention: Combination therapy (50 mg losartan daily and 10 mg enalapril daily)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Losartan (50 mg daily)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Enalapril (10 mg daily)
Number of subjects: 177
Study: 8598621

Group type: EXPERIMENTAL
Intervention: 600 mg of zileuton four times daily
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401

Group type: COMPARATOR
Intervention: 600 mg of zileuton, 400 mg of zileuton, or placebo
Number of subjects: 401
Study: 1421877

Group type: EXPERIMENTAL
Intervention: iv dexamethasone (n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: sham injections (n = 13)
Number of subjects: 25
Study: 6092309

Group type: EXPERIMENTAL
Intervention: COF (Cytoxan, Vincristin, and 5‐fluorouracil)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: COFP (Cytoxan, Vincristin, 5‐Fu and Procabazine)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Stage II
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Stage III
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Patients alive without evidence of disease
Number of subjects: 43
Study: 30107967

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) test
Number of subjects: 197

Group type: COMPARATOR
Intervention: Core laboratory (lab) test
Number of subjects: 197
Study: 27893064

Group type: COMPARATOR
Intervention: Lower-protein group (1 g of bovine protein/100 mL of breast milk)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Higher-protein group (1.8 g of bovine protein/100 mL of breast milk or individualized high-protein supplementation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lower-protein group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Higher-protein group
Number of subjects: 60
Study: 26304778

Group type: EXPERIMENTAL
Intervention: Stage of Change (SOC) tailored intervention
Number of subjects: 242

Group type: COMPARATOR
Intervention: Standard ergonomics advice
Number of subjects: 242
Study: 24330475

Group type: EXPERIMENTAL
Intervention: LVD-ADV combination therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: ADV monotherapy
Number of subjects: 72
Study: 21977923

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 300,000 IU of vitamin D3
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no vitamin D injection)
Number of subjects: 45
Study: 21126639

Group type: EXPERIMENTAL
Intervention: Coapsys ventricular reshaping
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control (indicated surgery: either coronary artery bypass graft alone or coronary artery bypass graft with mitral valve repair)
Number of subjects: 165
Study: 17878495

Group type: EXPERIMENTAL
Intervention: Combined thyroxine and triiodothyronine treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Thyroxine alone
Number of subjects: 9
Study: 15809670

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation therapy
Number of subjects: 76
Study: 11992421

Group type: EXPERIMENTAL
Intervention: Cigarette smoking for 30 years or more
Number of subjects: 89835

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 89835